Mechanism of action

Brensocatib inhibits dipeptidyl peptidase‑1 (DPP1), an enzyme responsible for activating neutrophil serine proteases (NSPs).
By inhibiting DPP1, it prevents activation of neutrophil elastase, proteinase‑3, and cathepsin‑G in neutrophil precursors.
This leads to:

Reduced neutrophil‑driven airway inflammation
Decreased lung tissue damage
Lower frequency of pulmonary exacerbations


Acts upstream of inflammation, unlike symptomatic anti‑inflammatory therapies.

Indication

Treatment of non‑cystic fibrosis bronchiectasis (NCFB) in:

Adult and pediatric patients ≥12 years of age